Loading...

Exelixis

DB:EX9
Snowflake Description

Outstanding track record with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EX9
DB
$6B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
EX9 Share Price and Events
7 Day Returns
-11.3%
DB:EX9
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
8.2%
DB:EX9
-10.6%
DE Biotechs
-6.2%
DE Market
EX9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Exelixis (EX9) -11.3% -13.9% -4.6% 8.2% 329.6% 674.4%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • EX9 outperformed the Biotechs industry which returned -10.6% over the past year.
  • EX9 outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
EX9
Industry
5yr Volatility vs Market

Value

 Is Exelixis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Exelixis to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Exelixis.

DB:EX9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 13 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:EX9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 21%) (0.24%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
7.99%

Discounted Cash Flow Calculation for DB:EX9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Exelixis is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:EX9 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.99%)
2019 238.62 Analyst x2 220.96
2020 306.37 Analyst x2 262.70
2021 333.95 Analyst x1 265.16
2022 477.61 Analyst x1 351.16
2023 656.13 Analyst x1 446.72
2024 780.20 Est @ 18.91% 491.88
2025 884.00 Est @ 13.3% 516.08
2026 966.94 Est @ 9.38% 522.72
2027 1,031.10 Est @ 6.64% 516.15
2028 1,079.70 Est @ 4.71% 500.48
Present value of next 10 years cash flows $4,094.01
DB:EX9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,079.70 × (1 + 0.23%) ÷ (7.99% – 0.23%)
$13,938.30
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $13,938.30 ÷ (1 + 7.99%)10
$6,460.95
DB:EX9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,094.01 + $6,460.95
$10,554.96
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,554.96 / 301.35
$35.03
DB:EX9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:EX9 represents 0.88229x of NasdaqGS:EXEL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88229x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 35.03 x 0.88229
€30.90
Value per share (EUR) From above. €30.90
Current discount Discount to share price of €18.18
= -1 x (€18.18 - €30.90) / €30.90
41.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Exelixis is available for.
Intrinsic value
41%
Share price is €18.18 vs Future cash flow value of €30.9
Current Discount Checks
For Exelixis to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Exelixis's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Exelixis's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Exelixis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Exelixis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:EX9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $2.32
NasdaqGS:EXEL Share Price ** NasdaqGS (2019-04-23) in USD $20.61
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Exelixis.

DB:EX9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:EXEL Share Price ÷ EPS (both in USD)

= 20.61 ÷ 2.32

8.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exelixis is good value based on earnings compared to the Europe Biotechs industry average.
  • Exelixis is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Exelixis's expected growth come at a high price?
Raw Data
DB:EX9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts
6.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:EX9 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 8.9x ÷ 6.5%

1.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exelixis is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Exelixis's assets?
Raw Data
DB:EX9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.29
NasdaqGS:EXEL Share Price * NasdaqGS (2019-04-23) in USD $20.61
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:EX9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:EXEL Share Price ÷ Book Value per Share (both in USD)

= 20.61 ÷ 4.29

4.8x

* Primary Listing of Exelixis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exelixis is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Exelixis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Exelixis has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Exelixis expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Exelixis expected to grow at an attractive rate?
  • Exelixis's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Exelixis's earnings growth is positive but not above the Germany market average.
  • Exelixis's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:EX9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:EX9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts 6.5%
DB:EX9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts 15.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:EX9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:EX9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,881 1,120 855 5
2022-12-31 1,641 965 668 7
2021-12-31 1,376 819 540 10
2020-12-31 1,170 519 437 13
2019-12-31 938 416 318 13
DB:EX9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 854 416 690
2018-09-30 745 364 368
2018-06-30 672 238 323
2018-03-31 585 169 253
2017-12-31 452 166 154
2017-09-30 410 197 150
2017-06-30 320 154 58
2017-03-31 257 122 6
2016-12-31 191 210 -70
2016-09-30 124 90 -147
2016-06-30 71 61 -181
2016-03-31 43 60 -186

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Exelixis's earnings are expected to grow by 6.5% yearly, however this is not considered high growth (20% yearly).
  • Exelixis's revenue is expected to grow by 15.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:EX9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below

All data from Exelixis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EX9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.64 3.34 2.14 5.00
2022-12-31 2.07 2.87 1.58 7.00
2021-12-31 1.69 2.42 1.11 8.00
2020-12-31 1.38 2.07 1.04 11.00
2019-12-31 1.00 1.35 0.69 11.00
DB:EX9 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 2.32
2018-09-30 1.24
2018-06-30 1.09
2018-03-31 0.86
2017-12-31 0.52
2017-09-30 0.52
2017-06-30 0.21
2017-03-31 0.02
2016-12-31 -0.28
2016-09-30 -0.62
2016-06-30 -0.80
2016-03-31 -0.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Exelixis is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Exelixis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Exelixis has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Exelixis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Exelixis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Exelixis has delivered over 20% year on year earnings growth in the past 5 years.
  • Exelixis's 1-year earnings growth exceeds its 5-year average (348.5% vs 69.5%)
  • Exelixis's earnings growth has exceeded the Europe Biotechs industry average in the past year (348.5% vs 18.2%).
Earnings and Revenue History
Exelixis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Exelixis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EX9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 853.83 690.07 206.37 182.26
2018-09-30 745.30 368.47 200.27 157.19
2018-06-30 672.41 322.97 190.28 140.99
2018-03-31 585.31 253.07 179.09 126.72
2017-12-31 452.48 153.86 159.36 112.17
2017-09-30 409.99 150.49 126.09 103.77
2017-06-30 319.67 58.08 120.42 95.48
2017-03-31 256.91 5.64 115.58 90.25
2016-12-31 191.45 -70.22 116.15 95.97
2016-09-30 123.81 -146.91 120.29 95.64
2016-06-30 71.47 -181.17 105.67 101.47
2016-03-31 43.21 -185.80 82.63 103.00
2015-12-31 37.17 -161.74 57.31 96.35
2015-09-30 34.59 -178.13 49.93 112.53
2015-06-30 31.02 -195.15 41.99 130.07
2015-03-31 29.59 -229.09 45.67 156.54
2014-12-31 25.11 -261.30 50.83 189.10
2014-09-30 22.11 -281.34 54.70 199.05
2014-06-30 21.28 -285.90 58.39 202.77
2014-03-31 26.57 -274.65 55.10 200.88
2013-12-31 31.34 -244.76 50.96 178.76
2013-09-30 34.81 -226.21 47.15 161.66
2013-06-30 42.65 -191.90 40.90 144.98
2013-03-31 38.61 -166.22 34.48 128.52
2012-12-31 47.45 -147.65 31.84 128.88
2012-09-30 132.94 -49.16 29.02 127.16
2012-06-30 247.90 61.52 29.85 133.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Exelixis made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Exelixis used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Exelixis has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Exelixis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Exelixis has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Exelixis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Exelixis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Exelixis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Exelixis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Exelixis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 59.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Exelixis Company Filings, last reported 3 months ago.

DB:EX9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,287.45 14.97 693.33
2018-09-30 915.97 14.98 634.62
2018-06-30 774.97 21.35 499.92
2018-03-31 669.77 0.00 426.92
2017-12-31 284.96 15.48 387.77
2017-09-30 238.72 0.00 367.10
2017-06-30 148.51 0.00 349.26
2017-03-31 119.75 113.35 424.27
2016-12-31 89.32 189.12 419.80
2016-09-30 32.02 190.86 319.68
2016-06-30 -186.13 396.06 328.12
2016-03-31 -155.95 388.66 322.12
2015-12-31 -140.81 417.94 167.06
2015-09-30 -74.23 377.89 197.81
2015-06-30 -188.19 371.23 76.60
2015-03-31 -146.76 368.43 107.25
2014-12-31 -114.83 356.97 144.29
2014-09-30 -58.51 355.22 192.00
2014-06-30 3.24 348.97 233.52
2014-03-31 71.48 343.02 273.57
2013-12-31 66.24 347.24 242.45
2013-09-30 132.76 341.59 279.22
2013-06-30 196.33 336.14 351.97
2013-03-31 254.85 330.85 356.56
2012-12-31 296.43 335.74 411.44
2012-09-30 340.85 335.29 472.35
2012-06-30 99.05 182.70 207.04
  • Exelixis's level of debt (1.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (523.7% vs 1.2% today).
  • Debt is well covered by operating cash flow (2777.9%, greater than 20% of total debt).
  • Exelixis earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Exelixis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Exelixis has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Exelixis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Exelixis dividends. Estimated to be 0% next year.
If you bought €2,000 of Exelixis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Exelixis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Exelixis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:EX9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:EX9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Exelixis has not reported any payouts.
  • Unable to verify if Exelixis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Exelixis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Exelixis has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Exelixis's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Exelixis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Exelixis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Exelixis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Exelixis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Morrissey
COMPENSATION $9,439,583
AGE 57
TENURE AS CEO 8.8 years
CEO Bio

Dr. Michael M. Morrissey, Ph.D., has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development at Exelixis Inc. since January 4, 2007 until July 2010. Dr. Morrissey served as an Executive Vice President of Discovery of Exelixis Inc., from January 2006 to December 2006 and its Senior Vice President of Discovery Research from January 2003 to December 2005. Dr. Morrissey served as Vice President of Discovery Research of Exelixis Inc. from February 2000 to December 2002. Dr. Morrissey served as Vice President of Discovery Research, where he was responsible for all aspects of drug discovery from 1991 to 2000 and Director of Pharmaceutical Discovery and Unit Head of Medicinal Chemistry of Berlex Biosciences, a pharmaceutical company. Dr. Morrissey led the effort to expand and modernize the drug discovery capabilities at Berlex through the application of high-throughput screening, combinatorial and medicinal chemistry and structural biology. Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal Chemistry of CIBA-Geigy Corporation, a pharmaceutical company from 1986 to 1991. Over the past nineteen years, Dr. Morrissey has led discovery efforts that identified 13 clinical candidates, including four that have advanced to Phase 2 clinical trials for a variety of cardiovascular and inflammatory indications. He has been a Director at Exelixis, Inc. since July 2010. Dr. Morrissey serves as Member of the Scientific Advisory Board of Resolvyx Pharmaceuticals, Inc. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 68 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds Ph.D. in Chemistry from Harvard University and his B.S. Honors in Chemistry from the University of Wisconsin.

CEO Compensation
  • Michael's compensation has increased by more than 20% in the past year.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Exelixis management team in years:

3.8
Average Tenure
57
Average Age
  • The tenure for the Exelixis management team is about average.
Management Team

Stelios Papadopoulos

TITLE
Co-Founder & Chairman
COMPENSATION
$328K
AGE
70

Michael Morrissey

TITLE
CEO, President & Director
COMPENSATION
$9M
AGE
57
TENURE
8.8 yrs

Chris Senner

TITLE
Executive VP & CFO
COMPENSATION
$4M
AGE
50
TENURE
3.8 yrs

Peter Lamb

TITLE
Executive VP of Scientific Strategy & Chief Scientific Officer
COMPENSATION
$3M
AGE
57
TENURE
12.3 yrs

Jeffrey Hessekiel

TITLE
Executive VP
COMPENSATION
$3M
AGE
49
TENURE
5.2 yrs

Gisela Schwab

TITLE
President of Product Development & Medical Affairs and Chief Medical Officer
COMPENSATION
$5M
AGE
61
TENURE
13.2 yrs

Dana Aftab

TITLE
Executive Vice President of Business Operations
TENURE
3.2 yrs

Susan Hubbard

TITLE
Executive Vice President of Public Affairs & Investor Relations
TENURE
2.3 yrs

Jon Berndt

TITLE
Vice President of Sales
TENURE
3.6 yrs

Gregg Bernier

TITLE
Vice President of Marketing
TENURE
3.6 yrs
Board of Directors Tenure

Average tenure and age of the Exelixis board of directors in years:

16.5
Average Tenure
64.5
Average Age
  • The average tenure for the Exelixis board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Michael Morrissey

TITLE
CEO, President & Director
COMPENSATION
$9M
AGE
57
TENURE
8.8 yrs

Charlie Cohen

TITLE
Independent Director
COMPENSATION
$328K
AGE
67
TENURE
23.4 yrs

Stelios Papadopoulos

TITLE
Co-Founder & Chairman
COMPENSATION
$328K
AGE
70
TENURE
21.3 yrs

Jack Wyszomierski

TITLE
Independent Director
COMPENSATION
$301K
AGE
62
TENURE
15.2 yrs

George Poste

TITLE
Independent Director
COMPENSATION
$306K
AGE
74
TENURE
14.7 yrs

Alan Garber

TITLE
Independent Director
COMPENSATION
$308K
AGE
62
TENURE
14.3 yrs

Lance Willsey

TITLE
Independent Director
COMPENSATION
$308K
AGE
56
TENURE
22 yrs

George Scangos

TITLE
Independent Director
COMPENSATION
$296K
AGE
70
TENURE
22.5 yrs

Vincent Marchesi

TITLE
Independent Director
COMPENSATION
$305K
AGE
82
TENURE
17.9 yrs

José Baselga

TITLE
Member of Scientific Advisory Board
AGE
58
TENURE
12.3 yrs
Who owns this company?
Recent Insider Trading
  • Exelixis insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Feb 19 Sell Patrick Haley Individual 25. Feb 19 25. Feb 19 -4,272 €19.62 €-83,835
20. Feb 19 Sell Charles Cohen Individual 14. Feb 19 19. Feb 19 -248,180 €19.78 €-4,849,255
01. Dec 18 Sell Jeffrey Hessekiel Individual 28. Nov 18 30. Nov 18 -14,818 €17.58 €-251,968
01. Dec 18 Sell Christopher Senner Individual 30. Nov 18 30. Nov 18 -8,791 €17.40 €-152,955
10. Nov 18 Sell Patrick Haley Individual 07. Nov 18 07. Nov 18 -20,000 €15.10 €-301,922
26. Sep 18 Sell George Scangos Individual 24. Sep 18 24. Sep 18 -25,000 €14.30 €-357,599
08. Aug 18 Sell Patrick Haley Individual 06. Aug 18 06. Aug 18 -2,361 €18.08 €-42,690
02. Jun 18 Sell Jeffrey Hessekiel Individual 31. May 18 31. May 18 -65,000 €17.76 €-1,154,593
02. Jun 18 Sell Carl Feldbaum Individual 30. May 18 30. May 18 -19,512 €17.71 €-345,514
25. May 18 Sell Lance Willsey Individual 22. May 18 22. May 18 -50,000 €18.16 €-908,216
19. May 18 Sell Patrick Haley Individual 18. May 18 18. May 18 -3,663 €18.36 €-67,260
08. May 18 Sell Patrick Haley Individual 04. May 18 04. May 18 -2,549 €18.76 €-47,822
08. May 18 Sell Jeffrey Hessekiel Individual 04. May 18 04. May 18 -20,000 €18.74 €-374,888
X
Management checks
We assess Exelixis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Exelixis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Details
Name: Exelixis, Inc.
EX9
Exchange: DB
Founded: 1994
$5,542,475,640
301,346,561
Website: http://www.exelixis.com
Address: Exelixis, Inc.
1851 Harbor Bay Parkway,
Alameda,
California, 94502,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS EXEL Common Stock Nasdaq Global Select US USD 11. Apr 2000
DB EX9 Common Stock Deutsche Boerse AG DE EUR 11. Apr 2000
LSE 0IJO Common Stock London Stock Exchange GB USD 11. Apr 2000
Number of employees
Current staff
Staff numbers
484
Exelixis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:48
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.